Tempest Therapeutics GAAP EPS of -$0.21 beats by $0.11
Tempest Therapeutics reported Q3 GAAP EPS of -$0.21, beating estimates by $0.11. The company had $0.9 million in cash and equivalents, down from $7.7 million at year-end 2025.
How this was made
The 30-second read
Why it matters
The earnings beat provides a small data point but does not materially change the company's loss trajectory.
Market read
Limited relevance; primarily of interest to investors in TPST and biotech micro‑caps.
What to watch
Cash balance dropped sharply to $0.9M, indicating liquidity concerns that may outweigh the earnings beat.
Background
Tempest Therapeutics is a clinical-stage biotech focused on immuno‑oncology.
Ticker impact
Tempest Therapeutics reported Q3 GAAP EPS of -$0.21, beating expectations by $0.11.
limited upside pressure as the market may view the beat as insufficient to change loss outlook
Earnings beat is positive but the absolute EPS is still negative; investors may be cautious.
Market effects
Biotech sector may see minor positive sentiment from a beat, but overall impact limited.
US biotech investors may note the result, no broader regional effect.
Minimal global relevance beyond the company.
Counterpoint
Despite the beat, the continued loss suggests the stock could face further downside if guidance remains weak.
Key entities
- companyTempest Therapeutics, Inc.
Biotech firm reporting Q3 results.